Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor Therapy in the Managed Care Era

1996 ◽  
Vol 78 (6) ◽  
pp. 32-41 ◽  
Author(s):  
Terry A Jacobson
1993 ◽  
Vol 21 (2) ◽  
pp. 105-111
Author(s):  
S Okada ◽  
K Ichiki ◽  
S Tanokuchi ◽  
Z Ota

Hydroxymethylglutaryl–coenzyme A (HMG–CoA) reductase inhibitor (pravastatin sodium) can selectively inhibit cholesterol biosynthesis in the liver and may lower serum cholesterol concentrations even where there are no particular dietary restrictions. A 72-year old housewife with non-insulin-dependent diabetes mellitus complicated by hyperlipaemia type IIb, who did not follow directions for diet therapy or kinesitherapy, was administered HMG–CoA reductase inhibitor. The initial dose of 10 mg/day HMG–CoA reductase inhibitor was increased by 10 mg/day every 4 weeks to 30 mg/day, maintained at 30 mg/day for 8 weeks and then reduced gradually until discontinuation after a further 27 weeks. Test results showed the changes in low-density lipoprotein cholesterol and apoprotein B to be dose-dependent. The findings represent the first clinical evidence that hypercholesterolaemia can be adequately managed by the use of HMG–CoA reductase inhibitor, even when no specific dietary restrictions are imposed, and may contribute to improvements in the quality of daily life for many patients suffering from hyperlipaemia type IIb.


2017 ◽  
Vol 5 (14) ◽  
Author(s):  
Hiroya Itoh ◽  
Makoto Matsui ◽  
Toshitaka Kumagai ◽  
Masanori Arita ◽  
Masayuki Machida ◽  
...  

ABSTRACT Fungal strain 14919 was originally isolated from a soil sample collected at Mt. Kiyosumi, Chiba Prefecture, Japan. It produces FR901512, a potent and strong 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitor. The genome sequence of fungal strain 14919 was determined and annotated to improve the productivity of FR901512.


Sign in / Sign up

Export Citation Format

Share Document